SG10201810067YA - Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents - Google Patents
Derivatives of uncialamycin, methods of synthesis and their use as antitumor agentsInfo
- Publication number
- SG10201810067YA SG10201810067YA SG10201810067YA SG10201810067YA SG10201810067YA SG 10201810067Y A SG10201810067Y A SG 10201810067YA SG 10201810067Y A SG10201810067Y A SG 10201810067YA SG 10201810067Y A SG10201810067Y A SG 10201810067YA SG 10201810067Y A SG10201810067Y A SG 10201810067YA
- Authority
- SG
- Singapore
- Prior art keywords
- uncialamycin
- methods
- present disclosure
- synthesis
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361865896P | 2013-08-14 | 2013-08-14 | |
US201361868783P | 2013-08-22 | 2013-08-22 | |
US201461937003P | 2014-02-07 | 2014-02-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201810067YA true SG10201810067YA (en) | 2018-12-28 |
Family
ID=51453866
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201601047SA SG11201601047SA (en) | 2013-08-14 | 2014-08-14 | Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents |
SG10201810067YA SG10201810067YA (en) | 2013-08-14 | 2014-08-14 | Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201601047SA SG11201601047SA (en) | 2013-08-14 | 2014-08-14 | Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents |
Country Status (13)
Country | Link |
---|---|
US (3) | US9777013B2 (zh) |
EP (1) | EP3033346B1 (zh) |
JP (2) | JP6474404B2 (zh) |
KR (1) | KR20160068738A (zh) |
CN (1) | CN105899515B (zh) |
AU (2) | AU2014306592B2 (zh) |
CA (1) | CA2921401A1 (zh) |
EA (1) | EA201690388A1 (zh) |
ES (1) | ES2769876T3 (zh) |
IL (1) | IL244084B (zh) |
MX (2) | MX368016B (zh) |
SG (2) | SG11201601047SA (zh) |
WO (1) | WO2015023879A1 (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6474404B2 (ja) | 2013-08-14 | 2019-02-27 | ウィリアム マーシュ ライス ユニバーシティWilliam Marsh Rice University | ウンシアラマイシン誘導体、合成方法、および抗腫瘍薬としてのそれらの使用 |
JP6564369B2 (ja) | 2013-12-09 | 2019-08-21 | デュレクト コーポレイション | 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法 |
KR20180057657A (ko) | 2015-09-23 | 2018-05-30 | 브리스톨-마이어스 스큅 컴퍼니 | 글리피칸-3-결합 피브로넥틴 기반 스캐폴드 분자 |
SG11201805150QA (en) | 2015-12-21 | 2018-07-30 | Bristol Myers Squibb Co | Variant antibodies for site-specific conjugation |
WO2018048975A1 (en) | 2016-09-09 | 2018-03-15 | Bristol-Myers Squibb Company | Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment |
EA202092747A1 (ru) | 2018-05-29 | 2021-03-16 | Бристол-Маерс Сквибб Компани | Модифицированные саморазрушающиеся фрагменты для применения в пролекарствах и конъюгатах и способы применения и изготовления |
LT3886914T (lt) | 2018-11-30 | 2023-05-25 | Bristol-Myers Squibb Company | Antikūnas, apimantis lengvosios grandinės c gale esantį glutamino turintį prailginimą, jo konjugatus ir metodus bei panaudojimo būdus |
WO2020123425A2 (en) | 2018-12-12 | 2020-06-18 | Bristol-Myers Squibb Company | Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses |
CN109928981B (zh) * | 2019-04-19 | 2021-06-11 | 长沙天赐生物医药科技有限公司 | 洋浦霉素类似物、制备方法及其应用 |
WO2021055306A1 (en) | 2019-09-16 | 2021-03-25 | Bristol-Myers Squibb Company | Dual capture method for analysis of antibody-drug conjugates |
US11027253B2 (en) | 2019-09-26 | 2021-06-08 | Chevron Phillips Chemical Company Lp | Systems and methods for reducing heat exchanger fouling rate |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
AU657910B2 (en) * | 1990-07-05 | 1995-03-30 | Akzo N.V. | Receptor directed-toxin conjugates |
US5281710A (en) | 1990-08-01 | 1994-01-25 | The Scripps Research Institute | Dynemicin analogs: synthesis, methods of preparation and use |
US5187297A (en) | 1990-11-05 | 1993-02-16 | Lonza Ltd. | Process for the production of 3-aminocrotononitrile |
US5162330A (en) | 1990-11-05 | 1992-11-10 | Bristol-Myers Squibb Co. | Dynemicin c antibiotic, its triacetyl derivative and pharmaceutical composition containing same |
US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
WO1996003124A1 (en) * | 1994-07-27 | 1996-02-08 | California Institute Of Technology | Dynemicin analogs |
GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
US5739169A (en) | 1996-05-31 | 1998-04-14 | Procept, Incorporated | Aromatic compounds for inhibiting immune response |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
US6232287B1 (en) | 1998-03-13 | 2001-05-15 | The Burnham Institute | Molecules that home to various selected organs or tissues |
US6528481B1 (en) | 1999-02-16 | 2003-03-04 | The Burnam Institute | NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods |
NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
US7452964B2 (en) | 2001-09-07 | 2008-11-18 | Board Of Regents, The University Of Texas System | Compositions and methods of use of targeting peptides against placenta and adipose tissues |
US7183388B2 (en) | 2001-03-30 | 2007-02-27 | The Regents Of The University Of California | Anti-MUC-1 single chain antibodies for tumor targeting |
US20060223114A1 (en) | 2001-04-26 | 2006-10-05 | Avidia Research Institute | Protein scaffolds and uses thereof |
US7671010B2 (en) | 2002-08-30 | 2010-03-02 | The Board Of Regents Of The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
US8507445B2 (en) | 2001-09-07 | 2013-08-13 | Board Of Regents, The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
CA2464690A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of apolipoprotein d |
CN1638800B (zh) | 2002-01-09 | 2014-07-16 | 梅达雷克斯有限责任公司 | 抗cd30的人类单克隆抗体 |
AU2003243436A1 (en) | 2002-06-06 | 2003-12-22 | Shohei Koide | Reconstituted polypeptides |
CN1826138B (zh) | 2003-07-22 | 2012-05-23 | 舍林股份公司 | Rg1抗体及其用途 |
WO2005051976A2 (en) | 2003-11-20 | 2005-06-09 | Ansata Therapeutics, Inc. | Protein and peptide ligation processes and one-step purification processes |
JP4806680B2 (ja) | 2004-05-19 | 2011-11-02 | メダレックス インコーポレイテッド | 自己犠牲リンカー及び薬剤複合体 |
MX2007005884A (es) | 2004-11-16 | 2008-02-12 | Amgen Mountain View Inc | Andamios de proteina y usos de los mismos. |
US7892827B2 (en) | 2004-11-26 | 2011-02-22 | Pieris Ag | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
MX2007009935A (es) | 2005-02-18 | 2007-10-10 | Medarex Inc | Anticuerpos monoclonales que carecen de residuos fucosilo contra antigeno membranal especifico de prostata (psma). |
US20090297438A1 (en) | 2005-02-18 | 2009-12-03 | Haichun Huang | Human Monoclonal Antibodies to Prostate Specific Membrane Antigen (PSMA) |
RU2406760C3 (ru) | 2005-05-09 | 2017-11-28 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
JP5215180B2 (ja) | 2005-06-20 | 2013-06-19 | メダレックス インコーポレーティッド | Cd19抗体およびその使用法 |
KR20080056167A (ko) | 2005-09-26 | 2008-06-20 | 메다렉스, 인코포레이티드 | 씨디70에 대한 인간 모노크로날 항체 |
WO2007038868A2 (en) * | 2005-10-03 | 2007-04-12 | The University Of British Columbia | Novel enediyne compound and uses thereof |
SG177194A1 (en) | 2005-12-08 | 2012-01-30 | Medarex Inc | Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and methods for using anti-ptk7 antibodies |
WO2007067991A2 (en) | 2005-12-08 | 2007-06-14 | Medarex, Inc. | Human monoclonal antibodies to o8e |
EP2002036A4 (en) | 2006-03-09 | 2010-01-27 | Univ Texas | COMPOSITIONS AND METHODS RELATING TO THE PROFILING OF MULTIPLE CELL LINES ON PEPTIDE BONDING BASIS |
DK2032606T3 (da) | 2006-05-30 | 2014-02-03 | Genentech Inc | Antistoffer og immunkonjugater og anvendelser deraf |
EP2035554B1 (en) | 2006-06-29 | 2013-04-24 | The Board of Trustees of The Leland Stanford Junior University | Cell-free synthesis of proteins containing unnatural amino acids |
CN101528914B (zh) | 2006-09-08 | 2014-12-03 | Ambrx公司 | 通过脊椎动物细胞位点特异性并入非天然氨基酸 |
BRPI0717902A2 (pt) | 2006-12-01 | 2013-10-29 | Medarex Inc | "anticorpo monoclonal humano isolado, composição, conjugado anticorpo-molécula parceria, imunoconjugado, molécula de ácido nucléico isolada, vetor de expressão, célula hospedeira, método para prepar um anticorpo anti-cd22, método para inibir o desenvolvimento de uma célula tumoral que expressa cd22 e método para tratar uma doença inflamatória ou autoimuneem um indivíduo" |
AU2007333098A1 (en) | 2006-12-14 | 2008-06-19 | Medarex, Inc. | Human antibodies that bind CD70 and uses thereof |
UY30776A1 (es) | 2006-12-21 | 2008-07-03 | Medarex Inc | Anticuerpos cd44 |
ES2562790T3 (es) | 2007-07-17 | 2016-03-08 | E. R. Squibb & Sons, L.L.C. | Anticuerpos monoclonales contra Glipicano-3 |
KR101554848B1 (ko) | 2007-10-01 | 2015-09-21 | 브리스톨-마이어스 스큅 컴퍼니 | 메소텔린에 결합하는 인간 항체 및 이의 용도 |
EP2653545A1 (en) | 2008-02-05 | 2013-10-23 | Bicycle Therapeutics Limited | Methods and compositions |
US8450278B2 (en) | 2008-10-15 | 2013-05-28 | Board Of Regents, The University Of Texas System | MUC18 targeting peptides |
WO2010087994A2 (en) | 2009-01-30 | 2010-08-05 | Whitehead Institute For Biomedical Research | Methods for ligation and uses thereof |
CA2864420C (en) | 2012-02-13 | 2016-11-15 | Naidu S. Chowdari | Enediyne compounds, conjugates thereof, and uses and methods therefor |
US8798431B2 (en) | 2012-06-01 | 2014-08-05 | Telefonaktiebolaget L M Ericsson (Publ) | Fine-grained optical shuffle interconnect topology migration |
JP6474404B2 (ja) | 2013-08-14 | 2019-02-27 | ウィリアム マーシュ ライス ユニバーシティWilliam Marsh Rice University | ウンシアラマイシン誘導体、合成方法、および抗腫瘍薬としてのそれらの使用 |
-
2014
- 2014-08-14 JP JP2016534843A patent/JP6474404B2/ja active Active
- 2014-08-14 MX MX2016001975A patent/MX368016B/es active IP Right Grant
- 2014-08-14 CN CN201480056718.0A patent/CN105899515B/zh active Active
- 2014-08-14 AU AU2014306592A patent/AU2014306592B2/en not_active Ceased
- 2014-08-14 ES ES14758223T patent/ES2769876T3/es active Active
- 2014-08-14 WO PCT/US2014/051127 patent/WO2015023879A1/en active Application Filing
- 2014-08-14 US US14/911,881 patent/US9777013B2/en active Active
- 2014-08-14 CA CA2921401A patent/CA2921401A1/en not_active Abandoned
- 2014-08-14 SG SG11201601047SA patent/SG11201601047SA/en unknown
- 2014-08-14 EA EA201690388A patent/EA201690388A1/ru unknown
- 2014-08-14 KR KR1020167006599A patent/KR20160068738A/ko not_active Application Discontinuation
- 2014-08-14 EP EP14758223.3A patent/EP3033346B1/en active Active
- 2014-08-14 SG SG10201810067YA patent/SG10201810067YA/en unknown
-
2016
- 2016-02-11 IL IL244084A patent/IL244084B/en not_active IP Right Cessation
- 2016-02-12 MX MX2019010875A patent/MX2019010875A/es unknown
-
2017
- 2017-08-15 US US15/677,959 patent/US10233192B2/en active Active
-
2019
- 2019-01-29 JP JP2019013008A patent/JP2019089804A/ja active Pending
- 2019-03-18 US US16/357,109 patent/US10889590B2/en active Active
- 2019-06-07 AU AU2019204034A patent/AU2019204034A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP6474404B2 (ja) | 2019-02-27 |
AU2014306592B2 (en) | 2019-04-04 |
CA2921401A1 (en) | 2015-02-19 |
SG11201601047SA (en) | 2016-03-30 |
JP2016534105A (ja) | 2016-11-04 |
ES2769876T3 (es) | 2020-06-29 |
MX2016001975A (es) | 2016-11-14 |
MX2019010875A (es) | 2019-12-19 |
EA201690388A1 (ru) | 2016-07-29 |
AU2014306592A1 (en) | 2016-03-10 |
US10233192B2 (en) | 2019-03-19 |
IL244084B (en) | 2019-08-29 |
IL244084A0 (en) | 2016-04-21 |
US9777013B2 (en) | 2017-10-03 |
US20180065976A1 (en) | 2018-03-08 |
US20190382412A1 (en) | 2019-12-19 |
CN105899515B (zh) | 2020-01-14 |
EP3033346B1 (en) | 2020-01-08 |
WO2015023879A1 (en) | 2015-02-19 |
KR20160068738A (ko) | 2016-06-15 |
US20160185791A1 (en) | 2016-06-30 |
CN105899515A (zh) | 2016-08-24 |
JP2019089804A (ja) | 2019-06-13 |
AU2019204034A1 (en) | 2019-07-04 |
MX368016B (es) | 2019-09-13 |
US10889590B2 (en) | 2021-01-12 |
EP3033346A1 (en) | 2016-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201810067YA (en) | Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents | |
CY1124061T1 (el) | Τρικυκλικη ενωση ως αντικαρκινικοι παραγοντες | |
WO2014197871A3 (en) | Antibody-drug conjugates, compositions and methods of use | |
PH12014501229A1 (en) | Antibody-drug conjugates and related compounds, compositions, and methods | |
ECSP16005566A (es) | Sulfonamidas como moduladores de canales de sodio | |
ES2821394T8 (es) | Compuestos de 7,8-dihidro-3H-pirazino[1,2-b]piridazin-3,5(6H)-diona y usos de los mismos | |
PH12016501232A1 (en) | Pyrazolo[1,5-a]pyridine derivatives and methods of their use | |
JO3773B1 (ar) | معدلات p2x7 | |
CR20150436A (es) | Nuevos octahidro-pirrolo[3,4-c]-pirrol y -piridina-fenilo | |
PE20151064A1 (es) | Nuevos derivados tienopirimidina, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
NZ705040A (en) | Fused pyrimidines as inhibitors of p97 complex | |
PH12016500643B1 (en) | NEW OCTAHYDRO-CYCLOBUTA [1,2-c;3,4-c'] DIPYRROL-2-YL | |
MY186547A (en) | 4?-fluoro-2?-methyl substituted nucleoside derivatives | |
CR20160070A (es) | Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos | |
ECSP088826A (es) | Compuestos heterocíclicos apropiados para tratar trastornos que responden a la modulación del receptor de serotonina 5ht6 | |
MX2015013740A (es) | Derivados de pirazolnaftridinona, preparacion y uso terapautico de los mismos. | |
MX2015014470A (es) | Analogos de combretastatina. | |
PL407152A1 (pl) | Pochodne 2',3'-dideoksy-5-fluorourydyny, sposób ich wytwarzania i zastosowanie | |
AR095353A1 (es) | Compuesto | |
UY32772A (es) | Etilamidas de benzotienilo novedosas y sus usos como microbicidas | |
CY1117740T1 (el) | Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης | |
NZ714357A (en) | Polycyclic ether compounds and their use in anticancer therapy | |
PL404920A1 (pl) | Nowe pochodne 3,4-dihydroizochinolino-3-karboksylowego o właściwościach przeciwnowotworowych, sposób ich syntezy, kompozycje farmaceutyczne zawierające te pochodne oraz ich zastosowanie | |
UY35348A (es) | Derivados de carbazol inhibidores del bromodominio y composiciones que los contienen |